Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
COSCIENS Biopharma Inc
T.CSCI
Alternate Symbol(s):
CSCI
Healthcare
Biotechnology
COSCIENS Biopharma Inc., formerly Aeterna Zentaris Inc., is a specialty biopharmaceutical company engaged in the development and commercialization of a diverse portfolio of pharmaceutical and diagnostic products, including those focused on areas of unmet medical need. Its lead product, macimorelin (Macrilen; Ghryvelin), is an oral test indicated for the diagnosis of adult growth hormone...
deficiency (AGHD). The Company is also engaged in the development of therapeutic assets and proprietary extraction technology, which is applied to the production of active ingredients from renewable plant resources used in cosmeceutical products (i.e., oat beta glucan and avenanthramides, which are found in skincare product brands like Aveeno and Burt’s Bees formulations) and being developed as potential nutraceuticals and/or pharmaceuticals.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (TSX:CSCI)
New Post
View:
Posts & Comments
Threaded Posts
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
Next
(109)
•••
prophetoffactz
X
View Profile
View Bullboard History
Post by
prophetoffactz
on Aug 12, 2024 2:02pm
Linkedin comment
Matthew H. JohnsonMatthew H. Johnson • 3rd+ • 3rd+Talent Driven Workplace Advice | Data Driven Real Estate Solutions | National Science, Innovation & Nonprofit Practice LeadTalent Driven Workplace
...more
(109)
•••
prophetoffactz
X
View Profile
View Bullboard History
Post by
prophetoffactz
on Aug 12, 2024 12:03am
Macrophages and COVID
J Exp Med . 2024 Jun 3;221(6):e20232192. doi: 10.1084/jem.20232192.
...more
BioVaxys Partner SpayVac for Wildlife, Inc., Scales-Up Vaccine Production Capacity
posted Nov 20, 2024 9:00am by
BioVaxys Technology Corp.
-
|
Kenneth Kovan, BioVaxys President & Chief Operating Officer, stated, "SpayVac for Wildlife, already a leader in developing breeding control, will leverage its scaled-up capacity to shorten the product-development cycle allowing them to further expand their pipeline using BioVaxys' technology platforms as engines for ...read more
(109)
•••
prophetoffactz
X
View Profile
View Bullboard History
Post by
prophetoffactz
on Aug 11, 2024 9:54pm
Oct. 8, 2024: A novel approach for scalable production
Pressurized Gas eXpanded (PGX) liquid Technology: A novel approach for scalable production of biopolymer aerogels and composites. (614) Tue, October 08
...more
(153)
•••
Hopeforthebest
X
View Profile
View Bullboard History
Comment by
Hopeforthebest
on Aug 11, 2024 5:53pm
RE:PGX Scale-up:
The original timeline for the 50l PGX scale up was the end of 2023 not 15 weeks ago in true gagnon he has never met an original self imposed timeline and who the hell knows when it will get done.
(109)
•••
prophetoffactz
X
View Profile
View Bullboard History
Post by
prophetoffactz
on Aug 11, 2024 3:14pm
NMOSD
Right now it is very hard for the market to value the NMOSD program. It's a preclinical program and preclinical assets are very uncertain with potential very risky timelines and cash burns. The
...more
(109)
•••
prophetoffactz
X
View Profile
View Bullboard History
Comment by
prophetoffactz
on Aug 11, 2024 2:21pm
RE:Avenanthramide pill
The Lancet Publishes Results from World's Largest Coronary CT Registry Showing New AI Technology Can Predict Cardiac Events Due to Coronary Inflammation At Least 10 Years in Advance
...more
(109)
•••
prophetoffactz
X
View Profile
View Bullboard History
Post by
prophetoffactz
on Aug 11, 2024 2:04pm
Avenanthramide pill
Avenanthramide was the reason Gilles wanted to join CZO originally. More recently, in a December 2022 news release Gilles stated: "...our avenanthramide program and could be the most significant
...more
(109)
•••
prophetoffactz
X
View Profile
View Bullboard History
Post by
prophetoffactz
on Aug 11, 2024 12:19pm
New Diagnostic Licensing Deal:
In July 2023, in a news release, AEZS said "...based upon our active outreach and discussions, we expect to secure an alternate development and commercialization partner for Macrilen®
...more
(109)
•••
prophetoffactz
X
View Profile
View Bullboard History
Comment by
prophetoffactz
on Aug 11, 2024 11:23am
RE:PGX Scale-up:
What percentage of the yeast beta glucan immune booster market could CSCI take with a potentially clearly superior source of yeast beta glucan further enhanced by PGX? CSCI and partner could have a
...more
(109)
•••
prophetoffactz
X
View Profile
View Bullboard History
Post by
prophetoffactz
on Aug 11, 2024 10:52am
PGX Scale-up:
Tomorrow will be 15 weeks since the scale-up of PGX to 50L was said "almost completed" after three trial runs. Three trial runs would allow a judgement concerning the repeatability of
...more
(153)
•••
Hopeforthebest
X
View Profile
View Bullboard History
Post by
Hopeforthebest
on Aug 09, 2024 11:42am
RE: PGX-YBG
proph said "Based on the average timeline from submission to the journal Biomaterials to publishing the comprehensive article on PGX-YBG/Fibrosis could be published within the next 30 days"
...more
(109)
•••
prophetoffactz
X
View Profile
View Bullboard History
Post by
prophetoffactz
on Aug 09, 2024 9:14am
PGX-YBG
Based on the average timeline from submission to the journal Biomaterials to publishing the comprehensive article on PGX-YBG/Fibrosis could be published within the next 30 days. In the October Small
...more
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
Discover Options Trading Strategies to Minimize your Tax Burden